CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	2029 Notes Conversion Option	At-The-Market Offering	Common stock	Common stock 2029 Notes Conversion Option	Common stock At-The-Market Offering	Additional paid in capital	Additional paid in capital 2029 Notes Conversion Option	Additional paid in capital At-The-Market Offering	Acc. Other Comprehensive Income	Treasury stock	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2023				157,287,522
Beginning balance at Dec. 31, 2023	$ (29,999)			$ 17			$ 303,428			$ 0	$ (57,350)	$ (276,094)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(127,792)											(127,792)
Foreign currency translation adjustments, net of tax	0
Equity-based compensation expense	5,157						5,157
Exercise of stock options (in shares)				64,544
Exercise of stock options	86						86
Issuance of shares for equity-based compensation awards, net (in shares)				4,096,003
Issuance of shares for equity-based compensation awards, net	(2,762)						(2,762)
Proceeds from exercise of warrants (in shares)				22,775,144
Proceeds from exercise of warrants	90,707			$ 2			90,705
Convertible debt conversion (in shares)				94
Issuance of shares purchased under ESPP (in shares)				0
Issuance of shares purchased under ESPP	0						0
Issuance of common shares as consideration for the acquisition of Pangiam (in shares)				61,838,072
Issuance of common shares as consideration for the acquisition of Pangiam	207,776			$ 6			207,770
Ending balance (in shares) at Mar. 31, 2024				246,061,379
Ending balance at Mar. 31, 2024	$ 143,173			$ 25			604,384			0	(57,350)	(403,886)
Beginning balance (in shares) at Dec. 31, 2024	251,554,378			251,554,378
Beginning balance at Dec. 31, 2024	$ (3,714)			$ 26			625,130			121	(57,350)	(571,641)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(61,986)											(61,986)
Foreign currency translation adjustments, net of tax	12									12
Equity-based compensation expense	$ 7,400						7,400
Exercise of stock options (in shares)	983,434			983,434
Exercise of stock options	$ 1,393						1,393
Issuance of shares for equity-based compensation awards, net (in shares)				3,120,222
Issuance of shares for equity-based compensation awards, net	(1,316)			$ 2			(1,318)
Proceeds from exercise of warrants (in shares)				14,800,000
Proceeds from exercise of warrants	$ 113,953			$ 1			113,952
Issuance of shares upon conversion of 2029 Notes/from at-the-market offering (in shares)					16,658,335	1,936,000
Issuance of shares upon conversion of 2029 Notes/from at-the-market offering		$ 135,599	$ 6,454		$ 2			$ 135,597	$ 6,454
Ending balance (in shares) at Mar. 31, 2025	289,052,369			289,052,369
Ending balance at Mar. 31, 2025	$ 197,795			$ 31			$ 888,608			$ 133	$ (57,350)	$ (633,627)